Home / Europe / United Kingdom / Life Sciences & Healthcare

Life Sciences & Healthcare

Discovery, innovation, market awareness and understanding are key to those life sciences and healthcare entities providing services and finance towards, and developing therapies and services for, the improvement of patient outcomes.

Due to the highly regulated nature of the industry, as an operator, investor, adviser, developer or licensee, you will be dealing with complex legal and regulatory requirements to launch, maintain and deliver your products and services to the market.

Our Life Sciences team is immersed in the sector and we appreciate our clients' technology; we are not just lawyers, we are immunologists, geneticists, chemists and engineers. With this background we are ideally placed to really understand your business, how it is changing and what you want from a trusted advisor. Highly relevant to this sector is our fully integrated European patent attorney practice. Spanning multiple disciplines, both legal and scientific, our lawyers and patent attorneys operate as one team with a common outlook and objective for our clients - providing pragmatic, innovative and effective advice, efficiently.

Our Healthcare team is truly immersed in the sector with over 25 years of advising and shaping the sector through in depth experience, knowledge and sector associations and collaborations. We have significant experience of working within the public and private sectors, giving us a complete perspective of the issues you face, allowing us to offer you commercial and well rounded advice.

We all also immersed in the sector’s clusters of expertise. This is part of our firm’s emphasis on global breadth with local depth, particularly in our local relationships. Our London office has excellent links within the “Golden Triangle”. We also have local teams who work closely with the Scottish clusters. For more information on our Scottish expertise, please see our specialist page, here.

With active memberships in major industry bodies such as the ABPI, ABHI, BIVDA, EUCOMED / MedTech Europe, Healthcare UK and the BPF, we help shape the legal and compliance frameworks impacting the life sciences and healthcare sectors.

As well as clients' significant, complex and strategic transactional, financing and structuring matters, we regularly advise on day-to-day business operations, covering areas such as public procurement, tax, competition, IP protection, exploitation and enforcement, product liability, supply chain, outsourcing and other commercial agreements and employment and pensions matters, as well as regulatory, disputes, risk and compliance advice. Truly a full service.

"Extensive pharmaceutical expertise with advice always provided in a business context. They understand our business and what we are trying to achieve with our IP strategy."

Legal 500, 2021

"CMS is one of the strongest city firms in this sector. They have real and deep rooted expertise. They deliver a Rolls-Royce service to some of the world’s most successful life sciences companies – many of whom they have deservedly achieved coveted “trusted adviser” status. They are one of the elite departments in this field. It is unsurprising that they have such a loyal client base."

Legal 500, 2021

"A one-stop-shop for us: its remarkable and successful mix of talent makes it stand out from the rest, and makes our lives much easier."

Chambers UK

Choose area

Recent years have seen an increase in the numbers of biotech IPOs and more investment in the sector, however it can still be challenging accessing the
microscope looking at a slide
Devices & Diagnostics
In an increasingly competitive healthcare market, medical device and diagnostics companies need to ensure return on investment when developing innovat
Laptop and stethoscope
With technology and digital innovation at the forefront of many advancements in the lifesciences industry and in healthcare delivery, organisations lo
Stethoscope lying on an ECG graph
We support clients across primary, acute, community, residential and social care including mental health, special education and children’s servi
scientist working with petri dishes
Life Sciences Disputes
Our Life Sciences disputes and investigations specialists advise clients across the breadth of the sector, including pharmaceutical, medical device an
Various bottles of chemicals
With ever increasing costs of gaining marketing authorisations for new drugs, fewer opportunities for blockbuster products and ongoing pressure on pri
equIP Life Sciences: from lab bench to business
Highlights of our experience in Life Sciences & Healthcare in the UK
Almirall, S.A., on the transfer of its respiratory franchise for an initial consideration of USD 875m on completion, and up to USD 1.22bn in development, launch and sales-related milestone payments. Johnson...
Law-Now: Lifesciences
Visit Law-Now for legal know-how and commentary


CMS Real Estate webinar: Repurposing the High Street for Life Sciences...
Candice Blackwood and Henrietta Oliver will share the key findings of our recent thought leadership piece about the transformation of the UK High Street, and the opportunities for life sciences and healthcare (including medical diagnostics) to fill the voids left by retailers.
In View: Life Sciences & Healthcare - What's new in AI Regulation and Data...
 We are delighted to invite you to the CMS In View: Life Sciences & Healthcare - What’s New in AI Regulation and Data Protection? event taking place on Thursday 18 April at our London Cannon Place offices. The seminar will focus on key AI and data protection topics relevant to life sciences and healthcare where you will hear from industry and regulatory experts from the ICO, Health Research Authority, UCL, the Wellcome Trust and CMS UK specialists. If you would like to attend this event, please register via the button below.
New and improved, or is it? – The CQC’s Single Assessment Framework
The new Care Quality Commission (CQC) single assessment framework is now in force for health and social care providers across England. As background, the new framework aims to provide a single vision...
Navigating clinical trial disclosures: No reasonable expectation of success...
Recent EPO Board of Appeal decision T 1437/21 adds to a growing number of decisions concerning the patentability of second or further medical use inventions where the prior art relates to a clinical trial...
Supreme Court ruling on the correct approach for assessing PSLA in “mixed...
In a judgment welcomed by claimants, the Supreme Court has upheld the Court of Appeal’s decision in the case of Hassam & Anor v Rabot & Anor [2023] EWCA Civ 19 in respect of the correct approach to...
Cannabis law and legislation in the UK
Medical use It is in principle lawful to produce, supply, offer to supply, import, export, have in possession or cultivate (in the case of the plant) cannabis products, including medicinal products...
Patentability of inventions relating to diagnostic methods at the EPO
Under Article 53(c) of the European Patent Convention (EPC), diagnostic methods practised on the human or animal body are excluded from patentability. The purpose behind this exclusion is to avoid patent...
Court of Appeal clarifies legal test of reasonable foreseeability in mesothelioma...
The Court of Appeal has issued important guidance on the legal test to be applied in establishing liability in asbestos-related mesothelioma claims. In a number of cases the Judgment will make it harder...
Court of Appeal determines costs budgeting issue in personal injury claims...
The Court of Appeal has decided that in principle, the Claimant’s solicitors’ costs of attending rehabilitation case management meetings are recoverable as costs of an action.This judgment is significant...
Court of Appeal rules that defence of illegality in civil claim is not...
In Lewis-Ranwell v G4S Health Services (UK) Ltd and others [2024] EWCA Civ 138, the Court of Appeal recently held, by a majority of 2 to 1, that where a person has committed a crime, but has been found...
Court of Appeal confirms position on damages for breach of public procurement...
The much anticipated judgment in the Braceurself appeal has been handed down by the Court of Appeal. The Court of Appeal (led by LJ Coulson) has reaffirmed the position established by the High Court that...
What’s in a name? Updated EMA guideline on naming medicinal products processed...
The updated EMA Guideline on the acceptability of names for human medicinal products processed through the centralised procedure was adopted by CHMP in December 2023 and came into effect on 1 January...